TW201642860A - 布羅莫結構域抑制劑 - Google Patents

布羅莫結構域抑制劑 Download PDF

Info

Publication number
TW201642860A
TW201642860A TW105112168A TW105112168A TW201642860A TW 201642860 A TW201642860 A TW 201642860A TW 105112168 A TW105112168 A TW 105112168A TW 105112168 A TW105112168 A TW 105112168A TW 201642860 A TW201642860 A TW 201642860A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
compound
methylsulfonylphenyl
cyclopropylmethoxy
methylisoquinolin
Prior art date
Application number
TW105112168A
Other languages
English (en)
Chinese (zh)
Inventor
貝坦科特胡安曼努爾
史塔福德傑佛瑞艾倫
史丹斯菲爾德萊恩
維爾詹姆士馬文
Original Assignee
塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 塞爾基因定量細胞研究公司 filed Critical 塞爾基因定量細胞研究公司
Publication of TW201642860A publication Critical patent/TW201642860A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW105112168A 2015-04-22 2016-04-19 布羅莫結構域抑制劑 TW201642860A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
TW201642860A true TW201642860A (zh) 2016-12-16

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105112168A TW201642860A (zh) 2015-04-22 2016-04-19 布羅莫結構域抑制劑

Country Status (22)

Country Link
US (1) US20160310423A1 (enExample)
EP (1) EP3285770A4 (enExample)
JP (1) JP2018513863A (enExample)
KR (1) KR20170139119A (enExample)
CN (1) CN107613981A (enExample)
AR (1) AR104340A1 (enExample)
AU (1) AU2016252992A1 (enExample)
BR (1) BR112017022691A2 (enExample)
CA (1) CA2983446C (enExample)
CL (1) CL2017002679A1 (enExample)
CO (1) CO2017011482A2 (enExample)
EA (1) EA201792317A1 (enExample)
EC (1) ECSP17071545A (enExample)
HK (1) HK1243948A1 (enExample)
IL (1) IL255120B (enExample)
MX (2) MX390077B (enExample)
PE (1) PE20180036A1 (enExample)
PH (1) PH12017501933A1 (enExample)
SG (1) SG11201708627TA (enExample)
TW (1) TW201642860A (enExample)
WO (1) WO2016172618A1 (enExample)
ZA (1) ZA201707186B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂
AU2017347853B2 (en) 2016-10-27 2022-02-17 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
JP7434274B2 (ja) * 2018-07-23 2024-02-20 セルジーン・クオンティセル・リサーチ・インコーポレイテッド ブロモドメイン阻害剤の合成方法
CN117136057A (zh) * 2021-02-22 2023-11-28 赛尔基因昆蒂赛尔研究公司 用于治疗前列腺癌的溴结构域(bet)抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
PE20161065A1 (es) * 2013-10-18 2016-11-19 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂

Also Published As

Publication number Publication date
CN107613981A (zh) 2018-01-19
HK1243948A1 (zh) 2018-07-27
AR104340A1 (es) 2017-07-12
EP3285770A4 (en) 2018-10-31
AU2016252992A1 (en) 2017-11-09
ECSP17071545A (es) 2017-12-01
MX2017013501A (es) 2018-02-09
CA2983446C (en) 2024-04-09
CA2983446A1 (en) 2016-10-27
MX377159B (es) 2025-03-07
PH12017501933A1 (en) 2018-03-19
CL2017002679A1 (es) 2018-05-25
SG11201708627TA (en) 2017-11-29
IL255120B (en) 2021-03-25
PE20180036A1 (es) 2018-01-09
EP3285770A1 (en) 2018-02-28
JP2018513863A (ja) 2018-05-31
BR112017022691A2 (pt) 2018-07-17
NZ736630A (en) 2024-03-22
CO2017011482A2 (es) 2018-01-31
MX390077B (es) 2025-03-20
US20160310423A1 (en) 2016-10-27
EA201792317A1 (ru) 2018-03-30
KR20170139119A (ko) 2017-12-18
WO2016172618A1 (en) 2016-10-27
ZA201707186B (en) 2019-01-30
MX2020010899A (es) 2022-02-15
IL255120A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
JP2024056905A (ja) ブロモドメイン阻害剤
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
CA3140412A1 (en) Compound for treating gout or hyperuricemia
US20230301983A1 (en) Bromodomain inhibitor
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN101830911B (zh) 一类噻吩并吡啶衍生物、其制备方法和用途
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии
HK40056574B (zh) 用於治疗或预防痛风或高尿酸血症的化合物的晶型